Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ledipasvir

- PMLiVE

Gilead under fire for Sovaldi anti-diversion policy

Accused as generic versions of the drug start to reach the market

- PMLiVE

Novartis knocks Pfizer off sales leader board

Swiss firm takes US giant’s crown as diversification programme and pipeline come to fruition

- PMLiVE

Top biotech firms saw sales jump in 2014

But rate of growth slowing from the past five years according to new analysis

Seismic shifts: Hepatitis C and payers

How hep C is causing paradigm changes in payer behaviour

- PMLiVE

The end of hepatitis C?

Next-gen hep C therapies may see the disease's global elimination - but treament access must be stepped up dramatically

- PMLiVE

Hepatitis C drugs drive US drug costs up in 2014

Played a role in a 13% increase in US prescription spending

- PMLiVE

Gilead’s Harvoni gains NICE yes – but won’t face funding delay

Unlike the company's Sovaldi, which won’t be paid for until the summer

- PMLiVE

Sovaldi-Daklinza combo cures hep C in co-infected HIV patients

Phase III trial of BMS and Gilead antivirals cured 97% of patients

Gilead Sciences

Gilead’s Sovaldi wins NICE approval but faces access delay

The Institute also recommends Janssen's hepatitis C drug Olysio

- PMLiVE

US lawmaker pushes for drug price transparency

If passed a new Bill would demand pharma show how product price tags are worked out

Gilead Sciences

Gilead agrees price cut for Sovaldi in Germany

Same sum as agreed with French government last November

Gilead Sciences

Gilead and Achillion see 100% success rate in hep C trial

New combination treatment aims to compete in a rapidly evolving market for the disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links